Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript Summary
Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript Summary
Cash burn for the quarter was approximately $5.6 million, including around $1 million in one-time or other annual payments.The following is a summary of the Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript:
以下是Movano Inc. (MOVE) 2024年第3季度業績會文本摘要:
Financial Performance:
財務表現：
Movano Inc. reported a decrease in operating loss from $9.1 million in the prior year period to $7.4 million in Q3 2024.
The company has $11.3 million in cash and cash equivalents as of September 30, 2024.
Cash burn for the quarter was approximately $5.6 million, including around $1 million in one-time or other annual payments.
Movano Inc.報告，從前一年同期的910萬美元減少至2024年第三季度的740萬美元的營運虧損。
截至2024年9月30日，該公司有1130萬美元的現金及現金等價物。
該季度現金消耗約爲560萬美元，其中包括約100萬美元的一次性或其他年度支付。
Business Progress:
業務進展：
Movano Inc. has engaged with multiple strategic partners in anticipation of an FDA 510(k) clearance for the EvieMED Ring.
Preparing for B2B commercial opportunities with healthcare partners post-FDA clearance.
Ongoing negotiations with a major global pharmaceutical company for leveraging EvieMED in building unique solutions for clinical and consumer applications.
Continued development and clinical trials for other medical technologies such as a cuffless blood pressure monitoring device.
Movano Inc.已與多家戰略合作伙伴合作，以期望獲得EvieMED Ring的FDA 510(k)許可。
在FDA許可後，爲20億美元的商業機會與醫療合作伙伴做準備。
與一家全球主要藥品公司進行持續談判，利用EvieMED構建獨特的臨床和消費者應用解決方案。
持續發展和臨床試驗其他醫療技術，如無袖血壓監測設備。
Opportunities:
機會：
EvieMED Ring offers significant potential for condition management, remote patient monitoring, clinical trials, and corporate wellness.
Movano's development of a cuffless blood pressure detection band opens avenues for new device introductions and enhancements under the Movano Health brand.
EvieMED Ring在控件管理，遠程患者監測，臨床試驗和企業健康方面具有重要潛力。
Movano開發的無袖血壓監測帶爲Movano Health品牌下新設備推出和增強開闢了新途徑。
Risks:
風險：
Delay or setbacks in achieving FDA 510(k) clearance for the EvieMED Ring may impact relationship and contract finalizations with B2B healthcare partners.
EvieMED Ring獲得FDA 510(k)審批出現延遲或挫折可能影響與B20億醫療合作伙伴的關係和合同最終化。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。